» Articles » PMID: 37584834

Enhancing Fear Extinction: Pharmacological Approaches

Overview
Publisher Springer
Specialty Psychology
Date 2023 Aug 16
PMID 37584834
Authors
Affiliations
Soon will be listed here.
Abstract

Extinction is the process by which the memory of a learned conditioned association decreases over time and with introduction of new associations. It is a vital part of fear learning, and it is critical to recovery in multiple fear-related disorders, including Specific and Social Phobias, Panic Disorder, Obsessive Compulsive Disorder (OCD), and Posttraumatic Stress Disorder (PTSD). The process of extinction is also the underlying mechanism for recovery in gold-standard therapies for PTSD, including prolonged exposure, cognitive processing therapy, eye movement desensitization and procession, as well as other empirically-based paradigms. Pharmacological modulators of extinction are thus promising targets for treatment of fear-related disorders. We focus here on emerging psychopharmacological treatments to facilitate extinction: D-cycloserine, scopolamine, losartan, ketamine, and 3,4-methylenedioxymethamphetamine. We also provide an overview of recent advances in molecular pathways that show promise as targets for extincion and inhibitory learning, including pathways related to cannabinoid, brain-derived neurotrophic factor, hypothalamic-pituitary-adrenal signaling, and promising work in neurosteroid compounds.

References
1.
Abdallah C, Roache J, Gueorguieva R, Averill L, Young-McCaughan S, Shiroma P . Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022; 47(8):1574-1581. PMC: 8767037. DOI: 10.1038/s41386-022-01266-9. View

2.
Albott C, Lim K, Forbes M, Erbes C, Tye S, Grabowski J . Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression. J Clin Psychiatry. 2018; 79(3). DOI: 10.4088/JCP.17m11634. View

3.
Amenta F, Mignini F, Rabbia F, Tomassoni D, Veglio F . Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data. J Neurol Sci. 2002; 203-204:147-51. DOI: 10.1016/s0022-510x(02)00281-2. View

4.
Andero R, Ressler K . Fear extinction and BDNF: translating animal models of PTSD to the clinic. Genes Brain Behav. 2012; 11(5):503-12. PMC: 3389160. DOI: 10.1111/j.1601-183X.2012.00801.x. View

5.
Andero R, Heldt S, Ye K, Liu X, Armario A, Ressler K . Effect of 7,8-dihydroxyflavone, a small-molecule TrkB agonist, on emotional learning. Am J Psychiatry. 2010; 168(2):163-72. PMC: 3770732. DOI: 10.1176/appi.ajp.2010.10030326. View